Pfizer has revealed plans for the birth of a new business division, global speciality and consumer brands, after completion of its $160-billion merger with Allergan.
Bill Meury, who currently heads up Allergan’s branded pharmaceuticals segment, is to lead the new unit, which will house Pfizer’s consumer healthcare unit and Allergan’s ophthalmology and aesthetics businesses, including Botox for therapeutic and cosmetic uses.
In other plans, after the transaction closes Pfizer’s Global Innovative Pharma (GIP) business will be combined with the Vaccines, Oncology and Consumer (VOC) division and will operate under the leadership of Albert Bourla, who will become group president, GIP.
Pfizer will continue to manage the combined company’s commercial operations through two distinct businesses: an Innovative Products business and an Established Products business.
The Innovative Products business will be composed of two operating segments: GIP and the Global Specialty and Consumer Brands segment, while the Established Products business will continue to be led by John Young, and consist of the Global Established Pharmaceutical segment, including all legacy Hospira commercial operations.
“We are designing the combined company to preserve and enhance our option to potentially separate the innovative and established businesses into separate companies in the future, and continue to expect to make a decision about any potential separation by no later than the end of 2018,” noted Pfizer’s chief executive Ian Read.
As previously announced, Brent Saunders will take charge as president and chief operating officer of the combined company with responsibility for the oversight of Pfizer and Allergan’s combined commercial businesses, manufacturing and strategy functions.
By Selina McKee
Source: Pharma Times
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
